Can a new drug play nice with common medicines? a trial investigates

NCT ID NCT07766369

First seen Aug 14, 2026 ยท Last updated Aug 14, 2026

Summary

This early-phase trial in healthy adults asks whether the experimental oral drug E2086 changes how the body processes several common medications, including an antifungal, a seizure drug, a sedative, a cough suppressant, an antidepressant, and birth control pills. Participants receive E2086 alone and with these other drugs to compare blood levels and safety. The goal is to understand potential drug interactions that could affect future dosing recommendations.

What this could mean

Our plain-language read of the trial. This is informational only โ€” not medical advice or a prediction.

Active substance
E2086, an experimental oral drug, tested alongside itraconazole, carbamazepine, midazolam, dextromethorphan, bupropion, and combined oral contraceptives
What this could lead to
If successful, this could help determine safe dosing of E2086 when taken with other common drugs, supporting its future development as a treatment.
What could go wrong
This is an early-phase study in healthy volunteers, not patients, so results may not predict real-world effects. Drug interactions could still occur in ways not captured here.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEALTHY VOLUNTEERS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • PPD Austin Clinical Research Unit (CRU)- Phase 1

    Austin, Texas, 78744, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.